<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">CHAWLA, SANT P.</style></author><author><style face="normal" font="default" size="100%">JEFFREY, SAMANTHA</style></author><author><style face="normal" font="default" size="100%">PANG, SKYLER S.</style></author><author><style face="normal" font="default" size="100%">JONES, ROBIN L.</style></author><author><style face="normal" font="default" size="100%">VAN GOOL, STEFAAN W.</style></author><author><style face="normal" font="default" size="100%">HUBER, TIMO</style></author><author><style face="normal" font="default" size="100%">KOSMAL, JENNIFER</style></author><author><style face="normal" font="default" size="100%">CHAWLA, NEAL S.</style></author><author><style face="normal" font="default" size="100%">CARTER, RHEANNA</style></author><author><style face="normal" font="default" size="100%">SIMONE, CHARLES B.</style></author><author><style face="normal" font="default" size="100%">NAEL, KAMBIZ</style></author><author><style face="normal" font="default" size="100%">BRUCKNER, HOWARD</style></author><author><style face="normal" font="default" size="100%">GATTANI, ANNA</style></author><author><style face="normal" font="default" size="100%">SONG, PAUL Y.</style></author><author><style face="normal" font="default" size="100%">HALL, FREDERICK L.</style></author><author><style face="normal" font="default" size="100%">GORDON, ERLINDA M.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Analysis of Clinical Benefit Using DNG64-&lt;em&gt;CAR-V&lt;/em&gt; Chimeric Tumor Targeted Amphotropic RNA Vector in &lt;em&gt;CCNG1&lt;/em&gt; Expressing Cancers</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2026</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2026-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2025-2034</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.18091</style></doi><volume><style face="normal" font="default" size="100%">46</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Metastatic cancer is almost always fatal, with few promising clinical options. DNG64-CAR-V is an off-the-shelf, replication-incompetent Chimeric Amphotropic tumor-targeted RNA Vector encoding a cytocidal Cyclin G1 (CCNG1) inhibitor construct.Patients and Methods: CCNG1 expression level in cancer types; Clinical benefit rate or CBR [complete response (CR), partial response (PR), or stable disease (SD)], confirmed by computed tomography or magnetic resonance imaging by RECIST v1.1; Overall response rate (ORR) and incidence and severity of adverse events were assessed. Eligibility criteria included: Previously treated male or female patients ≥12 years old with advanced sarcomas and patients ≥18 years old with advanced pancreatic ductal adenocarcinoma (PDAC), breast carcinoma or ovarian adenocarcinoma; Patients were treated with DNG64-CAR-V (1.7×1010 VC 3× a week × 3 weeks/month) plus metronomic low doses of FDA approved drugs (DNG64-CAR-V+); Statistical analysis was performed with Simon 2-stage design with Type I error rate=0.1 and power=0.8. A CBR ≥30% warrants a Phase II study using DNG64-CAR-V+ for CCNG1 expressing tumors.Results: Ten subjects with CCNG1 expressing sarcomas (n=6), PDAC (n=2), breast ductal carcinoma (n=1), and ovarian adenocarcinoma (n=1) were treated with DNG64-CAR-V+. Five of 10 (50%) had PR; 9/10 (90%) had clinical benefit. Median progression-free survival was 6.7 months for sarcoma. No serious treatment-related adverse event is reported.Conclusion: A response rate of 50% and a CBR of 90% for all groups meet the Simon 2-stage threshold of CBR &gt;30%, thereby qualifying all groups for a Phase II study using DNG64-CAR-V+ in CCNG1 expressing advanced cancers.</style></abstract></record></records></xml>